Bicifadine: Completed Phase IIb enrollment

XTL completed enrollment of 350 patients in a double-blind, international Phase IIb trial evaluating 200 or 400 mg bicifadine given three times daily vs. placebo. Last year, Dov granted XTL worldwide ...